



# Creating a World of Bionic Vision for Those Who Have Lost Their Sight




# Forward Looking Statements

This document contains information on Pixium Vision's markets and competitive position, and more specifically, on the size of its potential markets. This information has been drawn from various sources or from the company's own estimates. Investors should not base their investment decision on this information. This document also contains certain forward-looking statements. These statements are not a guarantee of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Pixium Vision draws your attention to the fact that as forward-looking statements cannot under any circumstance be construed as a guarantee of the Company's future performance and that the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operate may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Furthermore, even if Pixium Vision's financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this presentation. A description of those events that may have a material adverse effect on the business, financial position or results of Pixium Vision, or on its ability to meet its targets, appears in the sections "Risk Factors" of its "Document de Base" filed with the French Autorité des Marchés Financiers. By attending this presentation or accepting this document, you agree to be bound by the foregoing restrictions set out above.

# Create a world of bionic vision for those who have lost their sight



- **Pixium is a bioelectronics company** whose mission is to create a world of bionic vision for those who have lost their sight
- **PRIMA, a brain machine technology** comprises a miniaturized **retinal implant** which helps visually impaired patient regain sight through neuromodulation
- **7 patients already implanted** with Prima in Europe and USA
- The company is now moving from a research project phase to a **commercially oriented company**



Foundations Set in Place


Pixium Vision Enters its Next Phase

# Addressing a Large Unmet Need in Dry-AMD, Which Affects 80-90% of AMD Patients

## Age-related Macular Degeneration

- Eye disease leading to progressive loss of central vision
- Onset mostly around 60 years old
- Significant impact on quality of life, impeding ability to read, transportation interactions, and other daily tasks

**There is currently no approved treatment for dry AMD**



### Dry-AMD

**We believe Pixium's Prima System can become 1<sup>st</sup> approved Dry-AMD solution**


### Wet-AMD

- Treated by Lucentis and Eylea (\$10B in sales<sup>2</sup>)
- Often progresses to Dry-AMD

(1) Trans Am Ophthalmol Soc. 2005 Dec; 103: 173-186

(2) Based on 2018 Global sales: Lucentis (Roche/Novartis) \$3.7B and Eylea (Bayer/Regeneron) \$6.7B

# PRIMA : An Elegant Solution for Vision Restoration




2021 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited

2021 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited

# 7 patients already implanted in USA and Europe

## Final Pivotal Study underway in Europe



Data obtained from patient training session

### Word reading with second generation glasses

# Thank you

Lloyd Diamond, CEO | E: [ldiamond@pixium-vision.com](mailto:ldiamond@pixium-vision.com)

LinkedIn

